Related Experiment Video
Updated: Jun 11, 2026

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice
Published on: April 16, 2018
[Melatonin in the combined treatment of cardiovascular diseases]
Abstract:
The aim of the work was to assess effectiveness of melatonin monotherapy (MT) and combined treatment (CT) in aged patients with arterial hypertension (AH) and coronary heart disease (CHD). A group of 170 patients (mean age 64 years) included 61 ones with CHD and 100 with AH. ECG, AP, and echoCG monitoring was performed before and 21 days after treatment along with clinical examination and evaluation of oxidative and antioxidative activities in erythrocytes. Treatment efficiency was compared in the study and randomized control groups. The data obtained suggest antihypertensive action of MT. CT with melatonin and antihypertensive drugs had better outcome than standard therapy in control groups. Inclusion of melatonin in CT of CHD produced marked anti-ischemic and anti-anginal effects and normalized oxidant/antioxidant balance. It is concluded that melatonin should be an important component of MT and CT of cardiovascular diseases.
Related Concept Videos
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiovascular Drugs: Classification based on Therapeutic Indications